However, there is also research suggesting that RD development in cancer patients has a relation mostly to sex hormone deprivation therapies, such as aromatase inhibitors for breast cancer, antiandrogens for prostate cancer, and most recently, checkpoint inhibitors used in melanoma, urothelial cancer, and kidney cancer [18,19,20]. This evidence concerns the gene CYP19A1 and kidney cancer.